Clinical Trials Logo

Clinical Trial Summary

The present study explores whether a simultaneously given hepatitis A vaccine (Epaxal) will have an impact on the immune response to PCV13 (pneumococcal conjugate vaccine; Prevenar13) vaccine in adults. The immune response to PCV13 is measured as levels of serotype specific serum antibodies and their opsonophagocytic activity. The results of volunteers receiving PCV13 and Epaxal will be compared to that in a control groups of adults receiving either hepatitis A or PCV13 vaccines only.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms

  • Hepatitis
  • Hepatitis A
  • Measurement of Immune Response to Hepatitis A
  • Measurement of Immune Response to Prevenar13

NCT number NCT01926860
Study type Interventional
Source Helsinki University Central Hospital
Contact Anu Kantele, Assoc. prof.
Phone +358503097640
Email anu.kantele@hus.fi
Status Not yet recruiting
Phase Phase 4
Start date September 2013
Completion date September 2015